Pfizer Inc. (NYSE:PFE) Shares Purchased by Union Savings Bank

Union Savings Bank increased its position in shares of Pfizer Inc. (NYSE:PFE) by 3.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,999 shares of the biopharmaceutical company’s stock after purchasing an additional 626 shares during the quarter. Union Savings Bank’s holdings in Pfizer were worth $518,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Clifford Swan Investment Counsel LLC increased its position in shares of Pfizer by 4.7% in the fourth quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock valued at $12,007,000 after buying an additional 18,611 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after buying an additional 1,365,295 shares in the last quarter. LifePlan Financial LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at approximately $255,000. KLCM Advisors Inc. increased its position in shares of Pfizer by 75.0% in the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after buying an additional 74,487 shares in the last quarter. Finally, Farmers Trust Co. increased its position in shares of Pfizer by 2.0% during the fourth quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock worth $6,503,000 after purchasing an additional 4,410 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PFE. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Morgan Stanley upped their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets restated an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $35.86.

Pfizer Trading Up 3.6 %

PFE traded up $1.04 during mid-day trading on Wednesday, hitting $29.60. 46,109,194 shares of the stock were exchanged, compared to its average volume of 42,566,008. The firm’s fifty day moving average is $27.22 and its two-hundred day moving average is $27.96. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The company has a market cap of $167.73 billion, a PE ratio of -485.42, a PEG ratio of 1.20 and a beta of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the business earned $1.23 EPS. Pfizer’s revenue was down 19.5% on a year-over-year basis. Equities analysts forecast that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.68%. Pfizer’s payout ratio is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.